A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Tocilizumab Versus Placebo in Patients With Systemic Sclerosis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 29 Jan 2018
At a glance
- Drugs Tocilizumab (Primary)
- Indications Systemic scleroderma
- Focus Registrational; Therapeutic Use
- Acronyms focuSSced
- Sponsors Chugai Pharmaceutical; Roche
- 25 Jul 2017 Planned End Date changed from 31 Mar 2019 to 12 Feb 2019.
- 25 Jul 2017 Planned primary completion date changed from 1 May 2019 to 16 Jan 2018.
- 10 Jun 2017 Biomarkers information updated